百济神州主营产品名称 HK6160主营产品名称BGB-10188、BGB-11417、BGB-15025、BGB-A333、BGB-A425、BGB-A445、lifirafenibBGB-283、ociperlimabBGB-A1217、帕米帕利BGB-290、替雷利珠单抗注射液百泽安BGB-A317、泽布替尼胶囊百悦泽/BRUKINSABGB-3111
中国药品注册数据库提供CXSL1700104BGB-A333注射液的注册审评详情,包括BGB-A333注射液的药品类型治疗用生物制品,申请类型,药品信息,注册分类,批准文号.申报企业,承办日期以及CXSL1700104注册审评时光轴等信息.
(PD-L1) checkpoint inhibitors due to secondary or acquired resistance; therefore, there is a need to investigate novel PD-1/PD-L1 inhibitors.Methods This open-label, non-randomised study investigated the safety and anti-tumour activity of BGB-A333, a PD-L1 inhibitor, alone and in combination...
535MO BGB-A333, an anti-PD-L1 monoclonal antibody, in combination with tislelizumab in patients with urothelial carcinoma - ScienceDirectdoi:10.1016/j.annonc.2020.08.649J. Martin LiberalP.C. FongV. MorenoS. FrentzasJ. DesaiT. Meniawy...